Natera - NTRA Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings or view top-rated stocks.

7 analysts have issued 1-year price targets for Natera's shares. Their NTRA share price forecasts range from $54.00 to $110.00. On average, they anticipate the company's share price to reach $86.36 in the next twelve months. This suggests a possible upside of 83.6% from the stock's current price.
View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts.

Natera's stock was trading at $93.39 at the beginning of 2022. Since then, NTRA stock has decreased by 49.6% and is now trading at $47.03.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NTRA earnings forecast.

Natera, Inc. (NASDAQ:NTRA) announced its quarterly earnings data on Thursday, August, 4th. The medical research company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.47) by $0.03. The medical research company earned $198.20 million during the quarter, compared to analyst estimates of $193.67 million. Natera had a negative trailing twelve-month return on equity of 95.97% and a negative net margin of 79.57%. The firm's quarterly revenue was up 39.6% on a year-over-year basis. During the same period last year, the company posted ($1.32) EPS.

Natera issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $805.00 million-$825.00 million, compared to the consensus revenue estimate of $805.18 million.

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NTRA stock can currently be purchased for approximately $47.03.

Natera (NASDAQ:NTRA) has a market capitalization of $4.56 billion and generates $625.49 million in revenue each year. The medical research company earns $-471,720,000.00 in net income (profit) each year or ($6.06) on an earnings per share basis.

The company employs 2,670 workers across the globe.

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for the company is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com.